Abstract:Background: Updated prevalence estimates along the continuum of Alzheimer's disease (AD) can foster a more nuanced and effective approach to managing AD within the current healthcare landscape. Objectives: This study aims to estimate the prevalence and severity distribution of dementia/AD (including mild, moderate, and severe stages) and all-cause mild cognitive impairment (MCI) in the United States using data from the Health and Retirement Study (HRS). Design: Retrospective study. Setting: Data from the bi-annual HRS surveys involving in-depth interviews of a representative sample of Americans aged >50 years. Participants: Dementia/AD and all-cause MCI patients from the 4 most recent HRS surveys (2014, 2016, 2018 and 2020). Measurements: AD was identified based on diagnosis (self-report). Cognitive performance (modified Telephone Interview of Cognitive Status [TICS-m]) scores in the dementia/AD range were also captured; all-cause MCI was similarly identified using the TICS-m. Dementia/AD and MCI prevalence, as well as the distribution by dementia/AD stage (mild, moderate, or severe), were estimated. Sampling weights developed by HRS were applied to ensure the sample's representativeness of the target population and unbiased estimates for population parameters. Results: Across the four HRS surveys, the total number of HRS respondents ranged from 15,000 to 21,000 (unweighted); 7,000 to 14,000 had TICS-m scores. The estimated prevalence of AD (all severity categories combined) in the 2014, 2016, 2018, and 2020 HRS surveys was 1.2%, 1.2%, 1.3% and 1.0%, respectively using the diagnosis-based approach; using the cognitive performance-based approach, 23-27% patients had scores in the dementia/AD ranges across the 4 surveys. The estimated prevalence of all-cause MCI was consistently 23% in each survey. In the 2020 survey, the distribution of mild, moderate, and severe disease stages was 34%, 45%, and 21%, respectively, in patients self-reporting an AD diagnosis, and 55%, 40%, and 5%, respectively in all patients meeting TICS-m threshold for dementia/AD. Conclusion: The prevalence of AD diagnosis based on self-report was approximately 1% across the 4 most recent HRS surveys and may reflect the proportion of patients who have actively sought healthcare for AD. Among HRS survey respondents with cognitive scores available, over 20% were in the dementia/AD range. The distribution of disease by stage differed for self-reported AD diagnosis vs dementia/AD based on cognitive scores. Discordance in estimates of dementia/AD and stage distributions underscores a need for better understanding of clinical practice patterns in AD diagnosis, use of clinical assessment tools, and severity classification in the United States. Accurate patient identification is needed, especially early in the AD disease continuum, to allow for timely and appropriate initiation of new anti-amyloid treatments.

Prevalence Estimation of Dementia/Alzheimer's Disease Using Health and Retirement Study Database in the United States

Prevalence and Severity Distribution of Alzheimer’s Disease in the United States from the Health and Retirement Study

Prevalence of Alzheimer’s disease (AD) dementia and mild cognitive impairment (MCI) in the United States Medicare population

Prevalence of Mild Cognitive Impairment and Alzheimer's Disease Identified in Veterans in the United States

Prevalence of Alzheimer's disease dementia in the 50 US states and 3142 counties: A population estimate using the 2020 bridged‐race postcensal from the National Center for Health Statistics

Using a newly validated algorithm to estimate prevalence and incidence of Alzheimer’s Disease and related dementias in Medicare claims

Alzheimer’s Disease and Other Dementias in China: Secular Trend in Disease Burden from 1990 to 2019 and Projections to 2030

S3‐03‐04: Prevalence Study in Shanghai

Prevalence of Alzheimer’s dementia in the 50 U.S. states and 3142 counties: A population estimate using the 2020 bridged‐race postcensal from the National Center for Health Statistics

Real-world diagnostic, referral, and treatment patterns in early Alzheimer's disease among community-based practices in the United States

Robust Estimation of Dementia Prevalence from Two-Phase Surveys with Non-Responders Via Propensity Score Stratification

Approximating dementia prevalence in population-based surveys of aging worldwide: An unsupervised machine learning approach

Global estimates on the number of persons across the Alzheimer's disease continuum

Multi-National, Cross-Sectional Survey of Healthcare Resource Utilization in Patients with All Stages of Cognitive Impairment, Analyzed by Disease Severity, Country, and Geographical Region

Analysis of Alzheimer's Disease-Related Mortality Rates Among the Elderly Populations Across the United States: An Analysis of Demographic and Regional Disparities from 1999 to 2020

Demographics, comorbidities, and comedications in newly diagnosed patients with Alzheimer's disease and related dementias: Findings from United States Medicare claims data

PMU26 HEALTHCARE RESOURCE UTILIZATION AND CLINICAL OUTCOMES IN HOSPITALIZED PATIENTS WITH ALZHEIMER'S DISEASE AND RELATED DEMENTIAS IN THE UNITED STATES: A NATIONWIDE RETROSPECTIVE COHORT STUDY

The Prevalence of Dementia: A Systematic Review and Meta-Analysis

Economic Impact of Progression from Mild Cognitive Impairment to Alzheimer Disease in the United States

Forecasting the Prevalence of Alzheimer’s Disease at Mild Cognitive Impairment and Mild Dementia Stages in France in 2022

Early Detection of Dementia Using Risk Classification in MCI: Outcomes of Shanghai Mild Cognitive Impairment Cohort Study.